Sarah Cannon, the Cancer Institute of HCA Healthcare, offers integrated cancer services with convenient access to cutting-edge therapies for those facing cancer in communities across the United States and United Kingdom. Sarah Cannon’s cancer programs include individualized patient navigation provided by oncology-trained nurses, ~1,200 stem cell transplants performed annually throughout the Sarah Cannon Transplant and Cellular Therapy Network, hundreds of clinical trials, and molecular profiling capabilities. Through its services, Sarah Cannon is providing world-class cancer care close to home for hundreds of thousands of patients, a number unmatched by any single cancer center. To learn more about Sarah Cannon, visit sarahcannon.com.
Dr. Burris on Molecular Profiling in Breast Cancer
February 12th 2019Howard "Skip" A. Burris, III, MD, chief medical officer, Sarah Cannon Research Institute, 2019 ASCO president-elect, and a 2014 Giant of Cancer Care® in Drug Development, discusses the impact of molecular profiling in breast cancer.
Dr. Kambhampati on Frontline Ibrutinib Plus Obinutuzumab in CLL
February 6th 2019Suman Kambhampati, MD, co-medical director, Blood Cancer Program, Sarah Cannon Research Institute, discusses the combination of frontline ibrutinib plus obinutuzumab for the treatment of patients with chronic lymphocytic leukemia.
Dr. Burris Discusses Promise of T-DM1 in HER2+ Breast Cancer
February 5th 2019Howard “Skip” A. Burris, III, MD, chief medical officer, Sarah Cannon Research Institute, and a 2014 Giant of Cancer Care® in Drug Development, discusses the promise of T-DM1 in the treatment of patients with HER2-positive breast cancer.
Dr. Graff on Tamoxifen De-Escalation in Breast Cancer
February 1st 2019Stephanie L. Graff, MD, director of the Breast Program at the Sarah Cannon Cancer Institute of HCA Midwest Health, and associate director of the Breast Cancer Research Program at Sarah Cannon Research Institute, discusses the use of tamoxifen in the treatment of patients with breast cancer.
Dr. Yardley on the FDA Approval of Talazoparib in Breast Cancer
October 16th 2018Denise A. Yardley, MD, senior investigator of breast cancer research, Sarah Cannon Research Institute, discusses the FDA approval of talazoparib (Talzenna) for the treatment of patients with germline BRCA mutation–positive, HER2-negative locally advanced or metastatic breast cancer
Dr. Flinn on the FDA Approval of Duvelisib in CLL and Follicular Lymphoma
September 25th 2018Ian Flinn, MD, director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses the FDA approval of duvelisib (Copiktra) for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) or relapsed/refractory follicular lymphoma.
Dr. Graff on Novel Therapies in Metastatic Breast Cancer
September 21st 2018Stephanie L. Graff, MD, director, Breast Program, Sarah Cannon Cancer Institute, associate director, Breast Cancer Research Program, Sarah Cannon Research Institute, discusses novel therapies for patients with metastatic breast cancer.